Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.39 |
| ▸ | CCR2 | P41597 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027678 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP2C19ROCK2CCR2ROCK1 | |
| SCHEMBL3024088 | 0.82 | ROCK2 (0.39) | ROCK2CCR2ROCK1DPP4HDAC8 | |
| SCHEMBL5140554 | 0.81 | ROCK2 (0.50) | CYP2D6ROCK2CCR2ROCK1ACHE | |
| SCHEMBL3032958 | 0.79 | ALDH1A1 (0.40) | ROCK2CCR2ROCK1DPP4HDAC8 | |
| SCHEMBL3024792 | 0.79 | ROCK2 (0.51) | ROCK2CCR2ROCK1DPP4HDAC8 | |
| SCHEMBL5148134 | 0.79 | ROCK2 (0.51) | ROCK2CCR2ROCK1DPP4HDAC8 | |
| SCHEMBL5031248 | 0.76 | PGR (0.44) | CYP2D6ROCK2CCR2ROCK1DPP4 | |
| SCHEMBL3039765 | 0.76 | PGR (0.64) | CYP2D6 | |
| SCHEMBL3024142 | 0.76 | PGR (0.51) | CYP2D6DPP4HDAC8HDAC6POLB | |
| SCHEMBL3029883 | 0.75 | PGR (0.53) | CYP2D6ROCK2CCR2ROCK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216813-A1 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| EP-1954133-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007065093-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216813-A1 | PYRROLIDINEANILINES | PGF, ARG1, CYP19A1 | CYP2D6 2630/4885CYP2C19 553/4885ROCK2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.